London
Roots Analysis has announced the
addition of
Over time, extensive R&D on
the potential health benefits of cannabis, have enabled medical researchers to
identify a number of pharmacologically active ingredients that offer clinical
benefit, minus the addictive properties of the crude substance. Currently,
several stakeholders in the pharmaceutical industry are actively engaged in the
efforts to develop leads based on natural and synthetic derivatives of cannabinoids.
Key
Market Insights
Over 175 drugs targeting the endocannabinoid
system are currently under development
Most cannabinoid-based drug candidates
are being developed to target the CB1 and CB2 receptors. Nearly 45% of such drugs
are presently being investigated in clinical trials, while 50% are in the
preclinical / discovery phase. Majority of these
therapies (60%) are designed for oral administration.
More than 60 companies claim to
develop endocannabinoid system targeted therapeutics
Post 2010, there has been a
significant rise in the number of companies working in this domain; such
companies represent 63% of the total number of players. Majority of the firms
engaged in this domain (74%) are based in North America, followed by those
headquartered in Asia-Pacific (16%), Europe (8%) and Latin America (2%).
Partnership activity has
grown at an annualized rate of 35%, between 2017 and 2019
The maximum number of
partnerships were observed in 2019 within this segment of the pharmaceutical
industry. Majority of these agreements were reported to have been inked for research
purposes (20%). In addition, more than 35 merger / acquisition deal were signed
between 2016 and 2020; service / facility expansion emerged as the most
prominent key value drivers for such agreements.
Close to 600 grants were awarded
for supporting research on endocannabinoid system targeted therapeutics, since
2016
Almost 45% of the total amount
awarded in the form of grants, was under the R01 (in support of health-related
research and development based on the mission of the NIH) mechanism. Further,
grants (394) worth USD 147 million were awarded to research projects related to
endocannabinoid system.
At present, therapies intended
for the treatment of neurological disorders represent the majority share of the
overall endocannabinoid system targeted therapeutics market
Most of the therapies targeting neurological disorders are
intended for the treatment of epilepsy. In addition to neurological disorders, therapies
intended for autoimmune disorders, cancer and genetic disorders are likely to
capture significant market opportunity in the foreseen future.
Key
Questions Answered
§
§
§
§
§
§
§
The over USD 5 billion (by 2030) financial opportunity within
the endocannabinoid system targeted therapeutics
market has been analyzed across the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
The report features inputs from
eminent industry stakeholders, according to whom, endocannabinoid system
targeted therapeutics are considered as a promising alternative for the
treatment of a diverse array of symptoms associated with a myriad of human diseases.
The report includes detailed transcripts of the discussions held with industry experts.
§
§
§
§
§
§
The research includes detailed
profiles of key players (listed below); each profile features an
overview of the company,
§
§
§
§
§
§
§
§
§
§
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Neoantigen Targeted
Therapies
2.
3.
4. Continuous
Manufacturing
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
